ArticleDiscover oncology2025
Exploration of prognosis and immune infiltration characteristics in glioblastoma multiforme based on lipid metabolism related genes.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLipid metabolism reprogramming was a key adaptive mechanism for rapid proliferation of tumor cells. It affected tumor progression by altering the expression of lipid metabolism related genes (LMRGs). The aim of this study was to identify novel LMRGs-related prognostic biomarkers and therapeutic targets for glioblastoma multiforme (GBM).
methodsThe clinical and transcriptomic data of GBM patients were extracted from the TCGA database. the LMRGs were obtained from the MSigDB database, and screened for prognostic related genes. The immune cell infiltration status was evaluated using ESTIMATE, QUANTISEQ, CIBERSORT, MCPcounter algorithm and ssGSEA. The relevant signaling pathways were screened by the GO, KEGG, GSEA and GSVA analyses. The hub genes with prognostic value were screened through LASSO-Cox regression analysis. The distribution of the hub genes in GBM cells was determined by the TISCH2 database. Use DepMap database to demonstrate functional dependence of hub genes. Finally, validation was performed using the GEO dataset.
resultsWe divided GBM patients into two clusters, with cluster 2 (C2) had a worse prognosis than cluster 1 (C1) ( P = 0.0269 ), and C2 had higher abundance of M2 macrophages, NK cells and dendritic cells (DCs). 40 prognostic LMRGs were mainly enriched in lipid metabolism pathways such as steroid and phospholipid through GO/KEGG analysis. GSVA showed significant enrichment of phospholipid and steroid metabolism in C1. Four hub genes, INPP5F (hazard ratio > 1), PTEN, MTMR2 and IDI1, were identified through LASSO-Cox regression. Single-cell sequencing data showed a high proportion of oligodendrocytes in INPP5F-positive cells, and DepMap validation showed peak gene effects of INPP5F and IDI1 < 0, MTMR2 and PTEN>0.
conclusionWe have identified four prognostic LMRGs: INPP5F ( risk gene ), PTEN, MTMR2 and IDI1, which provide new insights into the mechanisms of GBM progression, as well as new prognostic biomarkers and immunotherapy targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.